Stokes Bio is dedicated to the development and application of microfluidic technology to radically improve and enhance life science research and molecular diagnostics. The company was founded in 2005 as a commercial spin-off from the Stokes Institute, at University of Limerick.
(Sold to Life Technologies)
2005
2006
Dr. Ed Walsh, Founding President UL appointed Chairman
2007
Technical progress: Prototype Liquid Bridge & parallel set working in unison
2008
LEK Consultants commissioned to review Stokes technology & potential market
2008
Kernel Capital’s total investment reaches €1.9m for 37%
2009
Kernel Capital worked with the founders to secure a License agreement with Monsanto
2009
The company’s Core Liquid Bridge patent granted
2010
Company acquired by Life Technologies for US$44m
“Kernel played a hands on role in all aspects of the business, sales, and corporate development, utilising their entire team. They assisted hugely in the corporate presentation of the Company. They introduced the Company to Monsanto and with the promoters attended multiple meetings with Monsanto in Missouri and Limerick, successfully closing a US$10m contract. When the opportunity to sell to Life Technologies arose, Kernel played a key role in the transaction and introduced IBI Corporate Finance to the Company who also played a superb role. Resulting in the Company being sold for US$44m in 2010.”
Prof. Mark Davies, Stokes Institute (Formerly Co-founder, Stokes Bio)
